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Gregory L. Moneta, MD, Section EditorRisk of Venous Thromboembolism Associated With Peripherally
Inserted Central Catheters: A Systematic Review and Meta-analysis
Chopra V, Anand S, Hickner A, et al. Lancet 2013;382:311-25.
Conclusions: Peripherally inserted central catheters (PICCs) are asso-
ciated with a higher risk of venous thromboembolism (VTE) but not a
higher risk of pulmonary embolism (PE) than central venous catheters
(CVCs). VTE risk is greatest in those who are critically ill or with cancer.
Summary: Use of PICC lines has increased dramatically secondary to
many associated therapeutic applications and increasing availability of nurse-
led PICC teams for PICC insertion. PICCs are known to be associated with
venous thrombosis. However, their relative risk compared with other forms
of CVCs is unknown. Understanding this risk may be important to assessing
costs and patient safety questions. The authors therefore performed a sys-
tematic review and meta-analysis to quantitate PICC risks for VTE
compared with other forms of CVCs. They also sought to determine the fre-
quency of PICC-related VTE in speciﬁc patient populations. The study was
conducted by searching databases that included MEDLINE, EMBASE,
BIOSIS, Cochrane Central Register of Controlled Trials, Conference Pa-
pers Index, and Scopus. Studies were also identiﬁed through hand searches
of bibliographies as well as Internet searches. In addition, the authors con-
tacted study authors to obtain unpublished data. Any human study pub-
lished in full text, abstract, or poster form was eligible. All studies were of
adult patients at least 18 years of age with PICC lines. The Newcastle-
Ottawa risk of bias scale was used to assess study bias. The pooled frequency
of VTE was calculated for patients receiving PICCs in studies without a
comparison group. In studies that compared PICCs with other CVCs,
odds ratios (ORs) for VTE were calculated using a random-effects meta-
analysis model. The authors identiﬁed 533 citations. Of these, 64 studies,
52 without and 12 with a comparison group, met eligibility criteria. There
were 29,503 patients analyzed in the 64 studies. In the noncomparison
studies, weighted frequency of PICC-related VTE was highest in patients
who were critically ill (13.91%; 95% conﬁdence interval [CI], 7.68%-
20.14%) and among those with cancer (6.67%; 95% CI, 4.69%-8.64%). In
the studies comparing the risk of VTE related to PICCs compared with
CVCs, PICCs were associated with an increased risk of VTE (OR, 2.55;
95% CI, 1.54-4.23; P < .0001). There were no PEs associated with PICCs.
Using the baseline PICC-VTE rate of 2.7% and a pooled OR of 2.55, the
authors concluded the number needed to harm with PICCs compared
with CVCs was 26 (95% CI, 13-71).
Comment: The fact PICCs are associated with high rates of VTE,
particularly in critically ill and cancer patients, is not surprising. It is also
not particularly surprising that PICCs are associated with a higher rate of
VTE than CVCs. It is intriguing that PICCs in this large study of
>29,000 patients were not associated with a single known case of PE.
One wonders, therefore, whether PICC-associated deep venous thrombosis
should be considered an adverse patient safety outcome as deﬁned by
Agency for Healthcare Research and Quality. This may reﬂect a differing
natural history of upper extremity venous thrombosis compared with lower
extremity venous thrombosis or perhaps, as the authors speculate, more
frequent development of thrombophlebitis with PICCs resulting in a “phys-
iologic barrier” against proximal embolism. Other factors, such as veriﬁca-
tion of PICC tip positioning and use of smaller-gauge PICCs, as well as
perhaps the fact that deep venous thrombosis in the arm may be more clin-
ically evident and lead to earlier treatment than that of the leg, may also play
a role in the vanishingly small incidence of PE associated with PICCs.
A New Revised Cardiac Risk Index Incorporating Fragmented QRS
Complex as a Prognostic Marker in Patients Undergoing Noncardiac
Vascular Surgery
Bae MH, Jang SY, Choi WS, et al. Am J Cardiol 2013;112:122-7.
Conclusions: The presence of a fragmented QRS complex from a
12-lead electrocardiogram (ECG) adds to the predictive value of the
Revised Cardiac Risk Index (RCRI) for predicting major adverse cardiac
events in patients undergoing noncardiac vascular surgery.
Summary: The RCRI is advocated by the American College of Car-
diology/American Heart Association Guidelines for perioperative risk
assessment in patients undergoing noncardiac vascular surgery (FleisherLA et al, Circulation 2007;116:e418-99; and Lee TH et al, Circulation
1999;100:1043-9). However, it is well known that the RCRI has, in fact,
relatively limited ability to predict perioperative cardiac events (Parmar
CD et al, Vasc Endovasc Surg 2010;44:14-9). After acute coronary syn-
drome, a fragmented QRS (fQRS) complex on a 12-lead ECG can predict
cardiac events that include death and heart failure progression. The ability of
fQRS to predict cardiac events in high-risk patients undergoing noncardiac
vascular surgery is unknown. The aim of this study was therefore to inves-
tigate a new RCRI that included consideration of fQRS in patients under-
going noncardiac vascular surgery. There were 467 consecutive patients
undergoing noncardiac vascular surgery who were studied. Patients were
allocated to RCRI 0, 1, 2, or $3 groups according to the presence of dia-
betes, renal insufﬁciency, and histories of ischemic heart disease, congestive
heart failure, and cerebrovascular disease. After including a score of 1 or 0,
corresponding to the presence or absence of fQRS, patients were then real-
located to fragmented RCRI (fRCRI) 0, 1, 2, or $3. Major cardiac adverse
events (MACE) were deﬁned as a composite of death, myocardial infarction,
congestive heart failure, and percutaneous coronary intervention before
noncardiac vascular surgery. During the index hospitalization, MACE
developed in 38 patients (8.1%), and fQRS was present in 169 (36.2%). It
was more frequently present in patients with MACE than in those without
MACE (63.2 % vs 34.3%, P < .0001). Proportions of RCRI 0, 1, 2, and $3
were 46.9% (n ¼ 219), 35.3% (n ¼ 165), 12.4% (n ¼ 58), and 5.4% (n ¼
25), respectively. Including fRCRI data, 28 patients (48.3%) in RCRI 2
were reclassiﬁed as fRCRI $3. Multivariate logistic regression analysis
showed fRCRI independently predicted in-hospital MACE in patients
undergoing noncardiac vascular surgery (odds ratio, 1.529; 95% conﬁdence
interval, 1.035-2.258; P ¼ .003).
Comment: Inclusion of fQRS upgraded 6% of the patients in this
study to a level where noninvasive imaging would be recommended before
noncardiac vascular surgery. It increased the sensitivity of the RCRI $3 for
predicting MACE by 10.5%, but sensitivity was still only 31.6%. There is still
room for a great deal of improvement in predicting perioperative cardiac
events in vascular surgery patients.
Renal Function 5 Years After Open and Endovascular Aortic
Aneurysm Repair From a Randomized Trial
de Bruin JL, Vervloet MG, Buimer MG, and the DREAM study group. Br J
Surg 2013;100:1465-70.
Conclusions: After 5 years, renal function after open and endovascu-
lar abdominal aortic aneurysm (AAA) repair (EVAR) is similar. Neither pro-
cedure accelerates loss of renal function.
Summary: Renal dysfunction is a concern after AAA repair, and renal
dysfunction is a strong predictor of impaired survival after vascular surgery
(Patel VI et al, J Vasc Surg 2012;56:1206-13). Absence of infrarenal aortic
cross-clamping appears to reduce the risk of renal dysfunction after EVAR
(Walsh SR et al, J Endovasc Ther 2008;15:73-82). However, contrast-
enhanced computed tomography scanning for post-EVAR surveillance
may negate presumed advantages of EVAR for kidney function. The authors
therefore sought to compare renal function 5 years after open and endovas-
cular repair of AAA. The study represents a post hoc analysis of data
collected prospectively from the Dutch Randomized Endovascular Aneu-
rysm Management (DREAM) trial. Creatinine levels 5 years after surgery
were available for 189 patients (94 after open repair and 95 after EVAR).
The U.S. National Kidney Foundation clinical guidelines were used to stage
severity of chronic renal disease. The estimated glomerular ﬁltration rate
(eGFR) was estimated using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation. Over time, eGFR for the entire group
declined, with a mean (standard deviation) preoperative value of 80.0 (7.6)
mL/min/1.73 m2 compared with 75.7 (9.7) mL/min/1.73 m2 after 5
years (mean difference, 4.2 [95% conﬁdence interval, 3.2-5.3] mL/min/
1.73 m2; P < .001). The mean eGFR 5 years after surgery was not signiﬁ-
cantly different between the open and endovascular groups: 76.3 (9.3) vs
75.1 (10.0) mL/min/1.73 m2 (P ¼ .410.)
Comment: Based on the National Health and Nutrition Examination
Survey III data, patients in the DREAM trial had lower preoperative mean
eGFR than age-matched, healthier counterparts (National Kidney Founda-
tion, Am J Kidney Dis 2002;39(Suppl 1):S1-266). However, the553
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repair is similar to that in the general population (Eriksen BO et al, Kidney
Int 2006;69:375-82). Surgeons can be assured, at least in a population with
mainly stage II chronic kidney disease, that open repair and EVAR for AAA
both are safe with respect to preservation of kidney function.
Risk of Stroke From New Carotid Artery Occlusion in the
Asymptomatic Carotid Surgery Trial-1
den Hartog AG, Halliday AW, Hayter E, and the Asymptomatic Carotid
Surgery Trial Collaborators. Stroke 2013;44:1652-9.
Conclusions: During long-term follow-up of patients with asymp-
tomatic carotid stenosis, occlusion and stroke were more common among
patients with $70% stenosis. Occlusion is an independent prognostic risk
factor for stroke.
Summary: In the Asymptomatic Carotid Surgery Trial (ACST), sur-
gery signiﬁcantly reduced 10-year stroke risk from 16.9% in those allocated
to expected management to 10.8% in those treated with carotid endarter-
ectomy (CEA) at the time of study entrance. Half the beneﬁt involved
disabling or fatal strokes (Halliday A et al, Lancet 2010;376:1074-84)
in patients who had a contralateral occlusion at time of entrance into
the ACST-1 trial (8%). There was similar beneﬁt in the annual event
rate in the immediate group (1.2%) and the deferred group (2.4%). How-
ever, no large-scale prospective studies have investigated stroke risk when
high-grade carotid stenosis progresses to occlusion. The ACST-1 trial pro-
vided the opportunity to analyze the incidence of new carotid occlusion
and stroke in the patients treated with expected management. In this
secondary analysis of ACST-1 data, the authors sought to determine the
risk of new carotid artery occlusion and associated stroke and to evaluate
risk factors predisposing to development of carotid occlusion. In the
ACST-1 trial, 3120 patients with high-grade asymptomatic carotid stenosis
were randomly assigned to medical treatment alone or to CEA and med-
ications. The analysis excluded 276 patients who had contralateral occlu-
sion at trial entry or incomplete duplex follow-up. Risk of new carotid
occlusion and stroke in patients with occlusion was estimated by Kaplan-
Meier analysis. Cox proportional hazard regression models were used to
determine risk factors for occlusion and stroke. Median follow-up in
2707 patients was 80 months (interquartile range, 52.0-115.0 months).
There were new occlusions in 197 patients (1.1% per year). New occlu-
sions were more likely to occur in arteries with tight stenosis and in non-
operated-on patients. Overall risk for stroke was 7.6% (95% conﬁdence
interval [CI], 6.6%-8.7%) and 15.5% (95% CI, 13.6%-17.4%) at 5 and
10 years, respectively. For patients with new carotid occlusion, the risk of
stroke increased signiﬁcantly to 17.0% (95% CI, 11.6%-22.4%) and 20.8%
(95% CI, 14.1%-26.2%) at 5 and 10 years, respectively (P < .0001). Stroke
was also signiﬁcantly more likely to occur in patients developing occlusion
(hazard ratio, 1.78; 95% CI, 1.26-2.51), irrespective of allocated treatment
in the ACST-1 study.
Comment: The data indicate that new carotid occlusions are infre-
quent in patients with asymptomatic carotid stenosis but that occlusion
and stroke are more common in patients who do not undergo CEA or in
whom there is a stenosis of $70% before occlusion. Occlusions occurring
in patients who had CEA seemed to be associated with less risk of stroke
than occlusions occurring in patients who did not undergo CEA, suggesting
that improved collateral circulation within the circle of Willis may decrease
the hazards of contralateral occlusion. CEA for high-grade stenosis in
asymptomatic patients, at least according to these data, appears beneﬁcial
in preventing stroke both ipsilateral and contralateral to the operated artery.
Delayed Management of Blunt Traumatic Aortic Injury: Open Surgical
Versus Endovascular Repair
Di Eusanio M, Folesani G, Berretta P, et al. Ann Thorac Surg
2013;95:1591-7.
Conclusions: Delayed management of thoracic aortic injury is associ-
ated with satisfactory short-term and long-term results, without signiﬁcant
differences between open and endovascular repair.
Summary: Blunt thoracic injury is the second most common cause of
death in trauma patients, following intracranial hemorrhage (Clancy TV et
al, J Trauma 2001;51:346-51). Delayed repair of blunt thoracic aortic injury
is associated with increased survival compared with immediate repair (Pacini
D et al, J Thorac Cardiovasc Surg 2005;129:880-4). The Society for
Vascular Surgery, using a meta-analysis that included 7768 patients from
139 studies, has suggested thoracic endovascular aortic repair (TEVAR) is
preferential treatment over open surgical repair or nonoperative manage-
ment for blunt thoracic aortic injury (Lee WA et al, J Vasc Surg
2011;53:187-92). The present study stratiﬁes short-term and long-term
outcomes of delayed management of blunt thoracic aortic injury accordingto type of repair: open surgical vs TEVAR. The authors have used delayed
aortic repair for treatment of blunt thoracic aortic injury since 1992.
Between 1992 and 2010, 77 patients with blunt thoracic injury were
managed. Patients were a mean age of 33.4 years, and 57 (74%) were
men. Of these patients, 31(41.3%) underwent open surgical repair because
they presented unstable or became unstable, and 44 patients (58.6%) under-
went TEVAR. Two patients died while awaiting aortic repair. There were
no deaths in the open surgical repair patients and only one death in the
TEVAR patients (P ¼ .398). No patient had postoperative paraplegia.
There was one posterior fossa stroke in a TEVAR patient who had inten-
tional coverage of the left subclavian artery. Follow-up at 95 6 70 months
(96.1% complete) showed no late deaths. At 15 years, survival and freedom
from secondary aortic procedures were 96% in the open surgical repair pa-
tients and 100% in the TEVAR patients.
Comment: The in-hospital mortality rates of blunt thoracic aortic
injury repair demonstrated in this report are extremely good. However,
the study is retrospective, and the possibility of signiﬁcant selection bias re-
mains. In the patients treated, however, it is noteworthy that treatment of
blunt thoracic aortic injury by open or TEVAR with an actuarial 15-year
follow-up seems to be extremely durable. In particular, there was no need
for revision of the TEVAR patients. These data substantiate the Society
for Vascular Surgical clinical guidelines suggesting that if no stent graft
migration or endoleak is noted at the initial follow-up computed tomogra-
phy scan 12 to 36 months after TEVAR for blunt thoracic aortic injury, an
appropriate follow-up for TEVAR for blunt thoracic aortic injury may be at
2-year to 5-year intervals.
Endovascular Repair of Type B Aortic Dissection: Long-term Results
of the Randomized Investigation of Stent Grafts in Aortic Dissection
Trial
Nienaber CA, Kische S, Rousseau H, and the INSTEAD-XL Trial
Investigators. Circ Cardiovasc Interv 2013;6:407-16.
Conclusions: Thoracic endovascular aortic repair (TEVAR), when
added to optimal medical treatment, is associated with improved 5-year
aorta-speciﬁc survival, improved aortic remodeling, and delayed disease
progression.
Summary: TEVAR has emerged as an option for patients with life-
threatening complications of type B aortic dissection. The role of TEVAR
in treatment of patients with initially uncomplicated aortic type B dissec-
tion is unknown. Whereas the short-term prognosis for uncomplicated
aortic type B dissection treated with optimal medical management is
good, long-term outcomes are disappointing because of aneurysm expan-
sion and a cumulative 30% mortality at 5 years (Suzuki T et al, Am J Car-
diol 2012;109:122-7). It is generally agreed that continued perfusion of
the false lumen of a type B aortic dissection is a predictor of adverse
outcome. On the other hand, complete thrombosis may result in aortic
remodeling and improved outcome. Two-year results of the Investigation
of Stent Grafts in Aortic Dissection (INSTEAD) trial demonstrated no dif-
ference in survival in the TEVAR vs medical management-only patients.
However, aortic remodeling appeared more favorable in the TEVAR-
treated patients. Given the apparent positive effect on aortic remodeling
at 2 years, it was hypothesized that endovascular treatment of type B
dissection might have longer-term prognostic beneﬁts. A total of 140
patients with stable type B aortic dissection were previously randomized
to optimal medical treatment and TEVAR (n ¼ 72) vs optimal medical
treatment alone (n ¼ 68). These patients were analyzed for aortic-speciﬁc
all-cause outcomes and disease progression using landmark statistical anal-
ysis of years 2 to 5 after the index procedure. Cox regression was used to
compare outcomes between groups. All analyses were based on intention-
to-treat. Risk of all-cause mortality (11.1% vs 19.3%; P ¼ .13), aorta-spe-
ciﬁc mortality (6.9% vs 19.3%; P ¼ .04), and progression (27.0% vs 46.1%;
P ¼ .04) after 5 years was lower with TEVAR plus optimal medical treat-
ment than with optimal medical treatment alone. Landmark analysis sug-
gested a beneﬁt of TEVAR for all end points between 2 and 5 years: all-
cause mortality (0% vs 16.9%; P ¼ .0003), aorta-speciﬁc mortality (0% vs
16.9%; P ¼ .0005), and progression of disease (4.1% vs 28.1%; P ¼
.004). Improved survival and less progression of disease at 5 years after
elective TEVAR were both associated with stent graft-induced false lumen
thrombosis in 90.6% of cases (P < .0001).
Comment: The data provide evidence that TEVAR for uncompli-
cated type B aortic dissection improves aortic remodeling and is associated
with improved 5-year survival. Beneﬁt does not appear, at least in this study,
to accrue until at least 2 years after treatment. Therefore, blanket use of
TEVAR for all patients with type B aortic dissection cannot currently be rec-
ommended if their life expectancy is <2 years. However, it does seem that
we now have evidence that for patients with reasonable life expectancy after
otherwise uncomplicated thoracic aortic dissection, preemptive treatment
with TEVAR will provide improved long-term outcome.
